(Corporate University Relations Manager, Schlumberger Ltd)

Dr. Najib Abusalbi is currently the Corporate University Relations Manager for Schlumberger Limited, the world's largest oilfield services provider. He joined Schlumberger in 1984 after three years of academic roles in Physics and Chemistry at University of Minnesota and University of Houston. Since 1984, he held multiple product development and management positions in several exploration and production domains – including information management director, operations manager, project director amnd program manager, as well as recruiting, training and career development manager, innovation and research director, chief architect for production & operations software in upstream oil & gas, and most recently held a position as university collaboration director for the Reservoir Characterization Schlumberger group of companies. Najib holds a PhD. in Atomic Physics from Louisiana State University and is recognized as a Technology Advisor in Schlumberger's Communities of Practice where he has led several communities including Management Disciplines, Project Management, and most recently Knowledge & Information Management. Andalibi, Ph.D.
(Associate Vice President for Research, Stony Brook University)

Dr. Andalibi is the senior advisor to the Vice President for Research and Deputy Operations Manager, and is responsible for the strategic direction of the Research Office with oversight of operations in the Offices of Research Initiatives & Assessment, Sponsored Programs, Grants Management, and the Office of Technology Licensing and Industry Relations. Dr. Andalibi works closely with deans, department chairs, faculty, departmental administrators, and university administration to improve research administration service and support for faculty and researchers through streamlined business models and implementation of programs that enhance Stony Brook's research competitiveness. He provides leadership on policy development in response to regulatory compliance requirements and serves as a liaison with SBU’s extramural sponsors. Dr. Andalibi represents Stony Brook with associations including the Council on Government Relations, Federal Demonstration Partnership and special task forces to the Association of American Universities. Before joining Stony Brook, Dr. Andalibi served as the Vice President of Research and Chief Scientific Officer at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Previous to that position, he served as a Program Director and head of the Therapeutics and Diagnostics Section in the National Cancer Institute’s SBIR Development Center. Dr. Andalibi received his PhD from the Department of Microbiology and Molecular Genetics in UCLA and later joined the faculty in the Department of Medicine in UCLA. Subsequently, he was involved in several early stage biotechnology companies. He then joined the House Ear Institute (HEI) as the Director of New Technology and Project Development and held a joint appointment in the Department of Otolaryngology at the University of Southern California, School of Medicine. Prior to moving to the NCI, Dr. Andalibi served as a Program Director in the National Science Foundation’s Division of Industrial Innovation and Partnerships, where he oversaw the NSF’s medical biotechnology SBIR/STTR grant portfolio. Alexei Andreev
(Executive Vice President and Managing Director, Harris & Harris Group)

Mr. Andreev is Executive Vice President and Managing Director of Harris & Harris Group, an early-stage, active investor in transformative nanotechnology companies. He is formerly an Associate with Draper Fisher Jurvetson (DFJ), a venture capital firm, where he was exclusively focused on nanotechnology and material science investment opportunities. He was graduated from the Department of Theoretical Physics of Moscow Steel & Alloys Institute (Ph.D.), Moscow Steel & Alloys Institute (B.S.) with honors in Engineering/Material Sciences and from Stanford Graduate School of Business (M.B.A.). Current portfolio responsibilities include: Adesto, Bridgelux, Cambrios, Contour Energy Systems, D-Wave Systems, Kovio, Molecular Imprints, NeoPhotonics (NYSE:NPTN), Ultora and Xradia. Ricardo Angel
(Managing Director, Energy Ventures, General Electric)

Ricardo Angel is a Managing Director at Energy Ventures where he leads origination for the business unit and for Energy Technology Ventures, a joint venture formed by GE, NRG Energy and ConocoPhillips focused on investing in emerging energy technology companies. GE Energy Ventures and Energy Technology Ventures seek investment opportunities across the energy value chain, including renewables, power infrastructure and oil & gas technologies. Mr. Angel joined GE from ChevronTexaco Technology Ventures' Venture Capital group. Previous experience includes investment banking at Goldman Sachs and consulting at CNA Corporation. Mr. Angel holds an MBA from Northwestern University's Kellogg School and Bachelors as well as Masters and Doctorate degrees in Engineering from the University of Illinois. He is based in San Francisco. Barbara Araneo, Ph.D.
(Director, Strategy and Sourcing, Diabetes Research Unit, Novo Nordisk)

Barbara Araneo, Ph.D., serves Novo Nordisk, Inc as the Director of Strategy and Sourcing in the Diabetes Research Unit. Previously, she was a member of the JDRF Research team as the Director of the Diabetes Complications Therapeutic Area, where her role was to create and manage a portfolio of externally funded research grants aimed at translation of primary discovery along the path of new therapeutics and biomarkers. Dr. Araneo served on the faculty of the University of Utah’s Department of Pathology as Associate Professor and has over 70 publications and 30 patents. In addition to her academic career, Dr. Araneo was Vice President of Development at StemCells Inc., where she was responsible for directing the effort to bring the company’s neural cell-based product candidate from the exploratory and preclinical proof of principle stages into clinical development under the FDA regulatory process. Prior to joining StemCells, Dr. Araneo was a Scientific Co-Founder and Senior Vice President of Research and Development at Pharmadigm, a privately held biopharmaceutical company with a number of products discovered at the company and developed for various stages of clinical development for inflammatory conditions. Over her career Dr. Araneo specialized in translational research concentrating on bringing disease-modifying targets through validation and drug proof of concept. She has led project teams to enable filing of INDs, communicate with the FDA and initiate first in man clinical trials. Dr. Araneo obtained her doctorate in Cellular Immunology from the University of Rochester and completed postdoctoral training at Washington University School of Medicine and the Department of Microbiology at UCLA. In addition to a doctorate degree, Dr. Araneo holds certification in US Regulatory Affairs. Errol Arkilic, Ph.D.
(Founder and President,

Errol is a Founder and the President of Founded in June of 2013, this organization's mission is to support the translation of academic-based research into products and services that address significant market needs. Previously, he was the founding and lead program director for the National Science Foundation Innovation Corps program. He led the I-Corps effort from its inception until July, 2013. Prior to this, Errol was the lead software and services program director for the NSF SBIR program. Before NSF, Errol was founder and CEO at StrataGent Lifesciences and the Manager of Product Engineering at Redwood Microsystems. Errol received his BS in Mechanical Engineering from George Washington University and his Master's and Ph.D. degrees in Aero/Astro Engineering from MIT. Tom Baruch
(Founding Member and Chairman, Formation 8)

Tom Baruch is a leading Venture Capitalist in San Francisco and Silicon Valley. Prior to becoming a founding member and Chairman of Formation 8, Tom formed CMEA Capital in 1988 with New Enterprise Associates (NEA), managing $1.2 billion of capital across seven funds through 2010. He led investments including major IPO’s and significant liquidity events for numerous technology companies. Tom worked at Exxon Mobil for 12 years, serving as President of the Materials Division before leaving in 1982. He then founded Microwave Technology, Inc., a semiconductor company where he served as CEO for 6 years. Tom is a member of the Executive Committee of the U.S. Council of Competitiveness  and serves as member of Obama’s National Advisory Council on Innovation and Entrepreneurship (NACIE). Tom holds an engineering degree from RPI and a Juris Doctor degree from Capital University. He is a member of the State Bar of Ohio and is a registered patent attorney. Robert E. Binder
(Founder and CEO, Antera Gestão de Recursos and Founder, Brazilian Venture Capital Association)

Robert E. Binder, US educated Brazilian economist with more than 40 years experience in capital markets, founder and CEO of Antera Gestão de Recursos, founder and previous Executive Director of the Brazilian Venture Capital Association (2000/ 2004), sometime entrepreneur who founded a market making company (BOVESPA) and a hotel management college In joint venture with a Swiss Institute, partner in three brokerage houses and founder of Agora CTVM (1994), CFO for Texaco Brazil (1985/1993), VP Marketing at Chase Manhattan Bank (1974/1980), and CVM (Brazilian SEC) accredited fund manager since 1994. Presently manages the Criatec Fund, the largest seed capital fund in Latin America, coordinates the Seed Capital, Innovation and Entrepreneurism Committee for ABVCAP and is a member of the Best Practices Committee formed between ANBIMA and ABVCAP to introduce self regulation in private equity. Antonio Jose Junqueira Botelho, Ph.D.
(Professor, Entrepreneurship and Innovation Policy, University Institute of Research of Rio de Janeiro IUPERJ/Universidade Cândido Mendes and Founding Partner, Innovastrat Consulting Ltd. and MPLC Brazil Ltda.)

Antonio Jose Junqueira Botelho PhD (MIT ’98) is Professor, Entrepreneurship and Innovation Policy at the Graduate Program in Political Science and International Relations, University Institute of Research of Rio de Janeiro IUPERJ/Universidade Cândido Mendes; Founding partner of the companies Innovastrat Consulting Ltd. and MPLC Brazil Ltda. He was professor of technology entrepreneurship, innovation management and innovative regions of PUC Rio (1999-2010). Botelho has been a long standing researcher of issues of venture capital and angel investment and is foundation mentor and Chairman of the Board (2011- today) of Gávea Angels, Latin America’s first and Brazil’s most active group of angel investors. He made angel investments in Descomplica (Brazil’s leading onine video education), JáComparou (telecom service comparison) and EasyFood (student nutrition monitoring). He is also a founder and is Treasurer of the Latin American Association of Angel Investors ALIA. Organizer of the I, II and III International Workshop of Latin America Angel Investors, the last one held in November 2012. He has participated in several meetings of the Angel Capital Association ACA (United States), having presented the work " Let 1,000 Angels Bloom OR Where’s the Exit? Angel Investment in Brazil (and Latin America) " in San Francisco last April; and of the European Business Angels Networks EBAN. He is the author of several publications, articles and presentations about venture capital and angel investment among others: "Angel Investment in Brazil", "Assessment of Transferable Knowledge from Asia and Europe", "From Entrepreneur to Angel Investor" and "From top flight executive to angel investor" in Angel Investing in Latin America (2005); and “Boosting the Take-off of innovation in Brazil: the angel investor, organizational dynamics” in the EnANPAD 2006-30th Meeting of the National Association for research in management, Salvador, Brazil, Botelho is the author of several publications and book chapters on science technology, innovation, entrepreneurship and development. He was the National Science Foundation, Division of Social, Behavioral, and Economic Research, Postdoctoral Research Fellow at Johns Hopkins University; and holds a PhD in Political Science from MIT; master's degrees from Université Paris IV and from Cornell University, and BSc in Geology from UFRJ (Brazil) James Caruso, Ph.D.
(General Manager, North America, JNC Corporation)

James Caruso is the General Manager, N. America for JNC Corporation. JNC, a $3B Japanese chemical company, is a market leader in display-related chemicals and materials including liquid crystals, OLED materials, overcoat materials, etc. Other JNC product families include advanced polymers, films, fibers and filter products along with agri-chemicals and various fine chemicals. Jim’s responsibilities include new business development, strategic partnerships and technical marketing. James is also a Venture Partner with Draper Nexus, an early-stage US-Japan cross border venture capital firm with teams in Tokyo and Silicon Valley - and part of the Global DFJ Network with a focus on Consumer Internet/Enterprise Services and Cleantech. James has a PhD in inorganic chemistry and an executive degree in strategic marketing. Prior to joining JNC, Jim had done 2 start-ups and was Director Sales/Marketing for a major US chemical company. Kevin Castello
(Executive Director, Baylor Angel Network)

Kevin Castello serves as the Executive Director of the Baylor Angel Network. As a Baylor MBA and Venture Fellow, Kevin brings significant deal flow analysis experience from his intern analyst role at G51 Capital. With an Entrepreneurial Finance focus, Kevin assists entrepreneurs with funding requests, analyzing investment opportunities for angel investors, managing analysts, and coordinating day-to-day network operations. His passion for start-ups and people provide relational synergy to all of the constituents of BAN. BAN has an intentional student participation model currently utilizing 6 senior student analysts. Kevin teaches in the undergraduate, MBA and EMBA programs on private equity investing and actively represents BAN with the Angel Capital Association, Angel Research Institute, Alliance of Texas Angel Networks, Baylor Business Network, and others. Kevin was recently named the inaugural Chairperson of the Alliance of Texas Angel Network Executive Director committee. In addition, Kevin manages several investment entities including the BAN G51 Investors, LLC; Affinity Angel Investment Fund I, LLC; and the BAN AV Fund I, LLC. He is the co-founder of Affinity Link, LLC which is a service provider to entrepreneurs and angel investors specializing in due diligence coordination, investment closing processes, and post-investment tracking. These services reduce the time and expense to entrepreneurs to close rounds, assure better communication between companies and investors, and facilitate an outsourced solution to investor relations for private firms. Affinity Link also specializes in angel investment fund management and their integration with affinity groups such as universities and economic development groups. Cervantez
(Co-Founder, Harvard Angels)

Tom is a Venture Partner at Accelerator Venture Capital and a founder of Business Counsel Law Group, LLP ( in San Francisco. Tom is active in the Silicon Valley early stage investing community on multiple levels. Tom is an active angel investor and founded the Golden Gate Angels, and co-founded the Harvard Angels, the HBS global angel community platform, and recently joined Accelerator Ventures as a Venture Partner. On the legal advisory side, Tom is a founding partner of Business Counsel Law Group in San Francisco, where he works with emerging companies, venture funds and computer software and hardware providers on corporate (including advising on angel, seed and VC funding terms and structures) and licensing matters. Tom received his BA from Loyola Marymount University and his JD/MBA from Harvard University. Chavez
(Director, AbbVie Biotech Venturs)

Margarita Chavez has 15 years of deal-making experience, with the last three years at AbbVie Biotech Ventures investing in biotech companies across the US and Europe. Margarita joined ABV from Abbott’s Global Pharmaceutical Licensing & Acquisitions, where she worked on a number of strategic transactions since 2007. Margarita was Senior Counsel in the Abbott Legal Division before that. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison, where she represented startups, venture funds and investment banks in financings, M&As and IPOs. JD 1997; BS 1994 Chen, Ph.D.
(Principal, New Ventures, University of Texas System Horizon Fund)

Dr. Wei Chen is a founding member of UT Horizon Fund at the University of Texas System. Dr. Chen leads the New Venture Program to bring R&D to marketplace. She is responsible for evaluating investment opportunity for the fund, creating new ventures, providing access to capital and business talents, and cultivating strategic partnerships. She also facilitates the technology commercialization and licensing process at UT institutions, and manages the relationship with investors, industry leaders and entrepreneurs. Prior to joining UT System, Dr. Chen was Vice President for New York Pacific Capital, a private equity fund focused on emerging growth market. Also she served as Business Development Specialist at the Technology Commercialization Office at the City University of New York, where she was responsible for the internal and external marketing for 23 campuses. Prior to that, she was one of the founding members of Yuxun Electronics, which is now a regional leader in China. Dr. Chen holds a PhD in Biophysics and MS in Physics from Indiana University Cohen
(Director, Innovation Ecosystem Development, University of California Berkley)

Mike drives initiatives, agreements and relationships that catalyze the commercialization of UC Berkeley innovations and support the funding of campus research. He has worked with over 70 startups. His initiatives include co-founding the Berkeley Startup Cluster, and QB3 East Bay Innovation Center -- a wet lab incubator for bioscience companies in West Berkeley. Mike conceived, co-championed and was the founding director (part-time) of the award winning Berkeley Skydeck -- an information technology-oriented startup accelerator in Downtown Berkeley. Mike also has been on the steering committees for the East Bay Green Corridor, and UC Berkeley's Cleantech-to-Market program. Prior to his leadership on the management of IP at UC Berkeley, Mike held board, executive, product management, marketing, business development and engineering positions at high tech companies including HP, Sun, Mips, SGI, Netpulse and Peak Democracy. Mike has co-founded two technology-based companies, and he has MBA and engineering degrees from Harvard and Tufts. Cooper
(Manager, Schlumberger Technology Investments)

Iain Cooper currently manages Schlumberger's Corporate Venturing activity, which he helped found in 2008. They currently have a portfolio of 11 companies and have also executed 4 exclusive license deals. Iain has over 21 years experience with Schlumberger in a range of technical and managerial positions in Drilling, Completions, Well Stimulation, Cementing and Coiled Tubing Services. Prior to his role managing Schlumberger's CVC group he was Global Product Development Manager for their Well Services division, and also previously Research Director for Drilling. Iain also looks after Schlumberger's relationships with major external technology companies. Iain recently co-authored and edited the Textbook on 'Advanced Drilling & Well Technology" for the Society of Petroleum Engineers, and has 26 granted US patents in a range of oilfield technologies. Iain is married with two children, and is based in Houston, Texas. Creek, Ph.D.
(Outside Innovation Manager Americas, Reckitt Benckiser)

John currently leads open innovation efforts for Reckitt Benckiser in the North and South America markets, supporting the full range of products, segments, and brands for RBs fast moving consumer goods business. This includes segments in Hygiene, Home, and Health. John graduated from Washington & Lee University with a BS in Chemical Engineering and from The Pennsylvania State University with a Ph.D. in Materials Science & Engineering. Since joining Reckitt Benckiser he has worked in a variety of R&D roles, including Intellectual Property Research, Technology Innovation, and Technology Sourcing. In his current position he works closely with R&D Category development and innovation teams to coordinate pipeline needs for the short, medium, and long term with both regional and global open innovation efforts led by the Outside Innovation Sourcing group. The team partners with universities, start-ups, SMEs, large companies in adjacent industries, and core suppliers to bring new innovations to life and commercialize them by leveraging RBs exceptional global consumer understanding, marketing, sales, and distribution channels. Eichenlaub
(Senior Director, Intel Labs Strategic Growth, Intel Corporation)

Steve has been with Intel since1998, and works in the Strategy Planning and Venturing group in Intel Labs, where he focuses on helping incubate and bring towards market promising breakthrough technologies and business opportunities from both inside and outside Intel. Prior to his current role, he spent 14 years as a Managing Director in Intel Capital, the venture investment arm of Intel, managing a team driving Platform Technologies, Cleantech, and Healthcare investments worldwide. Ahead of Intel, Steve worked at Adobe Systems and Mentor Graphics, and start-ups Silicon Compiler Systems and GammaMetrics, across a variety of roles spanning venture investing, M&A, business development, strategic and product marketing, sales, and investor relations. He holds a BS in Engineering from UC Berkeley, and an MBA from Harvard Business School. Ghose
(Partner, Information Technology, ONSET Ventures)

Shomit Ghose joined ONSET Ventures in 2001 after 19 years of working at high-tech companies in the Silicon Valley. During his career he participated in several successful IPOs, including those of Sun Microsystems and Broadvision. Prior to joining ONSET, he was Sr. VP of Operations at Tumbleweed Communications, where he managed the marketing, professional services, applications engineering and corporate development departments. He helped the company through a successful IPO in 1999. Previously, he was VP of the Worldwide Professional Services Organization at BroadVision and helped that company through a successful IPO in 1996. At ONSET Ventures, Shomit focuses on software, networking and infrastructure companies. He also mentors and provides management resources to portfolio companies to help maximize their success.

Michael Guptan
(Managing Director, Dell Ventures)

Michael is a Managing Director at Dell where he leads strategic investment and acquisitions activities in the Software Sector for Dell Ventures and Corporate Development.  Michael has more than 20 years of experience in the technology industry with a focus on investments, corporate strategy and software development. Michael has worked at some of the leading firms, including McKinsey & Company, Citigroup, Credit Suisse, JP Morgan and Hewlett Packard. Michael received his M.B.A. in finance from The Wharton School at the University of Pennsylvania. He also has an M.S. in computer science from University of Minnesota.  Michael is a board member at the Lincoln Center Institute, adjunct lecturer at New York University and a member of Wharton Private Equity Partners.

Michael Gutch
(Managing Director, MedImmune Ventures)

Mike joined MedImmune Ventures in September 2011.  Before MEVE, Mike was a Director with H.I.G. BioVentures, a life-science focused investment fund and prior to that was a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Mike was also in the Corporate Financing and Investment Banking group, where he focused on M&A and licensing transactions.  Mike earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York and was a post-doctoral research fellow at both UCSF and the Cold Spring Harbor Laboratories.  He earned his M.B.A. in finance from Indiana University.  Mike currently serves as a member of the Board of Directors for Southeast BIO, a member of the Johns Hopkins Alliance for Science & Technology Development, and a member of the Business Advisory Boards for the Alzheimer’s Drug Discovery Foundation and National Brain Tumor Society.

Steve Hahn
(Research Fellow, The Dow Chemical Company)

Steve joined Dow in Midland, Michigan in 1982 and has worked in a variety of business and corporate research and new business development functions at Dow prior to assuming his current role in 2007. As Research Fellow, Steve leads Dow’s effort to identify emerging, strategically aligned chemical, materials, water and energy related business opportunities. He is focusing on the North American West Coast region and is currently located in the San Francisco/Silicon Valley area of Northern California. Steve has a B.S. in Chemistry from Michigan Tech and an M.S. in Chemistry from Central Michigan University. He holds 38 issued U.S. Patents, has 40 publications in refereed journals, and 6 chapters in scientific reference books. Steve was named a Dow Inventor of the Year in 1990 and 1996, the Distinguished Alumni Lecturer at Michigan Tech in 1996and 2003, and received the Dow Excellence In Science Award in 1999. He was a Visiting Professor of Chemistry and IPrime Scholar at the University of Minnesota in 2002. He received the American Chemical Society Cooperative Research Award in 2008 and the Council for Chemical Research Collaboration Award in 2010. He has represented Dow on Advisory Boards at the University of Connecticut and at Michigan Tech. Steve also serves on the advisory board for the Global Social Venturing Competition at the Haas School of Business at UC-Berkeley.

Mark Heesen
(President, National Venture Capital Association)

Mark Heesen has advocated for the venture capital industry, entrepreneurship and innovation for nearly two decades, first as NVCA’s head of public policy and, since 1999 as the Association’s president. Under Mark’s leadership, the NVCA has grown in both scope and scale as it relates to its public policy agenda, research initiatives, and member programs. Mark is constantly engaged in legislative and regulatory issues surrounding information technology, life sciences and clean technology investing, providing strategic direction for the NVCA professional staff and managing a board of 26 venture capital practitioners. Mark has taken a leadership position on behalf of the venture capital industry on issues such as carried interest taxation, financial services reform, the FDA regulatory approval process, highly skilled immigration, patent reform, U.S. competitiveness issues, energy reform, support for basic research funding and countless other policy issues that impact America’s entrepreneurial ecosystem. As the primary spokesperson for the venture capital industry, Mark is often called upon by the financial media, NVCA members, limited partners, and regional associations to offer insights and perspectives on trends and developments occurring within the asset class. He is a frequent presenter at industry conferences, a familiar and trusted source in news articles focusing on the venture industry, and a recurrent guest on CNBC and Bloomberg Television.

Martin Heidecker, Ph.D.
(Director, Investment Manager, Boehringer Ingelheim Venture Fund)

Martin joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. Prior to BIVF, Martin held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. Martin began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. Martin holds a PhD in Biology as well as a Master degree in Biology and Economics.

Henrik Hollandimages/conference2013/speaker/holland.jpg
(Venture Principal, Shell Technology Ventures)

Henrik Holland is a Venture Principal at Shell Technology Ventures, the corporate venturing arm of Shell. STV helps Shell identify, adopt, and deploy new technologies faster, making minority investments in technology ventures that look promising for delivering a meaningful competitive advantage. Partners of Shell technology Ventures benefit from access to Shell’s strong innovation network; its global customer, supplier and contractor base; the ability to do field trials; and Shell’s strong brand and reputation. Mr. Holland started his career in telecommunications with Alcatel-Lucent and Telefonica. During his 10 years with Shell, Henrik worked in upstream oil & gas operational and business development roles, and has been responsible for Shell’s end-to-end relationships with various Fortune 100 technology companies.

Marianne Hudson
(Executive Director, Angel Capital Association and Angel Resource Institute)

Ms. Hudson leads two nonprofit organizations: the Angel Capital Association (ACA), the professional alliance of angel groups in North America, with 20 affiliates and 170 member groups representing 8,000 individual accredited investors, and the Angel Resource Institute (ARI), which provides information, education, and research about angel investing to investors, policy makers, university leaders, entrepreneurial support professionals, and entrepreneurs. ARI was founded by the Ewing Marion Kauffman Foundation in 2005 and spun out of Kauffman as an independent charitable organization in March, 2007. Ms. Hudson led the angel initiative at the Kauffman Foundation that resulted in ARI and also oversaw many of the Foundation’s entrepreneurial education and mentoring programs designed to ensure that more entrepreneurs develop sustainable, innovative businesses. Ms Hudson has worked in the entrepreneurial support field for more than 25 years. She holds a B.A. in Economics and Political Science from the University of Kansas and an M.A. in Public Policy from Rutgers University.

Sean Jacobsohn
(Co-President and Co-Founder, Harvard Business School (HBS) Alumni Angels, Venture Partner, Emergence Capital)

Sean Jacobsohn is a Venture Partner at Emergence Capital after being an executive and advisor at Emergence Capital portfolio companies YouSendIt and Doximity, respectively. Prior to YouSendIt, he was VP of Channel Management at Cornerstone OnDemand (CSOD). Sean helped grow the company from $7 million to $75 million in revenue and 300,000 subscribers to over 7.5 million, the second most of any software-as-a-service company in the world. Before his tenure at Cornerstone OnDemand, Sean was VP Sales and Partner Development at WageWorks (WAGE), which grew from $3 million to $82 million in revenue during his tenure. Jacobsohn has an MBA from Harvard Business School and a BBA in Marketing, Finance, and International Business from University of Wisconsin. In addition to serving on the HBS Alumni Board and Satmetrix board, he is co-President and co-founder of the HBS Alumni Angels, the largest university-affiliated angel group in the world.

Elaine Jones, Ph.D.
Executive Director - Venture Capital, Pfizer Venture Investments)

Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital in 2008. She is responsible for making and managing venture investments for Pfizer and currently manages the PVI investments in Aquinox Pharmaceuticals (Vancouver, British Columbia), Flexion Therapeutics (Boston, MA), Mersana Therapeutics (Cambridge, MA), Merus B.V. (Utrecht, The Netherlands), Neuronetics Inc. (Malvern, PA), NeuroTherapeutics Pharma (Chicago, IL), and TetraLogic Pharma (Malvern, PA). Elaine brings 12 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team. Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept. Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.

Christina Karapataki
Venture Principal, Early Stage Technology Investments, Schlumberger)

Christina Karapataki is a Venture Principal in the Early Stage Technology Investments group at Schlumberger Technology Corporation. She focuses in early stage investments in energy, advanced materials and sustainability technologies. Prior to her current role, Christina worked for ExxonMobil Gas & Power Marketing in both the European and North America offices, and gained venture experience evaluating oil and gas technology investments with Venrock Management LLC in 2011. Christina’s background is in Chemical Engineering with B.A. and M.Eng. degrees from the University of Cambridge. She is a graduate from MIT, with an S.M. degree in Energy Technology and Policy, where her research at the MIT Energy Initiative focused on evaluating water management technologies for shale gas production operations.

Clint Korver
Co-Founder and Co-President, Stanford Angels and Entrepreneurs and Co-Founder and Partner, Ulu Ventures)

Clint is a co-founder and partner at Ulu Ventures, an early stage investment firm in Silicon Valley. He focuses on startups in enterprise SaaS, online education, and predictive analytics and has made over 50 investments. He is a co-founder and co-president of Stanford Angels and Entrepreneurs and teaches entrepreneurship at Stanford. He leads Kauffman Fellows Academy, which offers online training programs in entrepreneurship and innovation investing in partnership with the Kauffman Fellows Program. Prior to becoming an investor and a teacher, he co-founded and led two technology and two service companies. He holds a PhD and an MS in Management Sciences and Engineering from Stanford University, and a BA, with Honors, in mathematics from Grinnell College where he serves as Chair of the Board of Trustees.

Nety Krishna, Ph.D.
Partner, Bright Capital)

Nety Krishna is a Partner at Bright Capital since 2012. At Bright, Nety focuses on developing a robust pipeline of investment opportunities in the Energy and IT sectors, building strong relationships with key partners and helping to promote the opportunities available to companies in Russia and neighboring regions. Prior to joining Bright, Nety was a Partner at Redpoint Ventures where he was a lead member of the Energy, Materials & Environment investment team. The investments covered many sectors including CO2-to-Chemicals, Energy Storage, Efficient Materials Discovery, Solid State Lighting, Smart Grid, Nuclear Fusion and PV. Nety has a strong science and technology background having spent more than 13 years as an executive at Applied Materials – a leader in the semiconductor equipment and materials industries. His contributions led to the commercialization of many cutting edge technologies that are industry standards today. Nety received his MS and PhD degrees in Particle Physics from Rice University.

Valery Krivenko
General Partner, FPI Partners)

Valery Krivenko is General Partner of FPI Partners, a VC firm focused on developing businesses with early stage industrial B2B technologies. FPI invests in US and Europe and actively engages cross border technology and business development opportunities in US, Europe, Israel, Russia and FSU. Valery is an active investor in high-tech startups in US, Germany, Canada, Russia as an individual. Previously Valery worked as Managing Partner of Bright Capital, a VC firm focused on clean-tech; Head of High-tech Investments at ONEXIM Group, one of the leading investment holdings in Russia with AUM of $20 bln. Prior to that Valery was Director for Business Development at Sibur. In 2001-2006 Valery was with McKinsey & Company where he worked on various projects in Russia and Europe focusing on private equity, strategy, M&A, and performance management. Valery holds an MBA degree from London Business School and M.S. in International Economics from MGIMO University.

Steve Kubisen, Ph.D.
Director, Office of Technology Transfer, The George Washington University)

Steve is a serial entrepreneur, corporate executive and university technology commercialization executive. He started his career in research and then moved to research management and general management for Union Carbide, Akzo Coatings, GE and Alcoa. During his 8 years with GE, as General Manager of GE Electromaterials, he commercialized a revolutionary circuit board material for the emerging computer and telecommunications industries and as General Manager of R&D and Engineering of the $500M GE Silicones Division instituted systems to double new product sales. As an entrepreneur, Steve was CEO of a revolutionary composite manufacturing venture and a medical device venture, in addition to serving on boards of a number of early stage ventures. Steve’s passion for commercializing early technologies and growing entrepreneurial communities led him to university technology commercialization operations. For over 7 years, he served as Vice President of Utah State University’s Office of Technology Commercialization and Senior Director of Ventures and the Medical Device/Software/Engineering Portfolio Group at The Johns Hopkins University. During his 4 year tenure at Utah State, Steve tripled licensing revenue and moved the institution into the top five in the nation for start-ups per research dollar. During his 3 year tenure at Hopkins, the institution increased start-ups from a historical annual level of 4 to 12 in 2008, with $76M venture capital raised. Steve has an A.B. in chemistry from Cornell University and a Ph.D. in organic chemistry from Harvard University.

Steve Kuemmerle, Ph.D.
Deputy Director, UChicagoTech, University of Chicago)

Steve Kuemmerle is the Deputy Director of UChicagoTech, the University of Chicago’s Center for Technology Development & Ventures. He leads a team that is responsible for building relationships with faculty, for helping to shape and prosecute University intellectual property, and for commercial assessment and licensing of University inventions into existing and start-up companies. Steve brings close to three decades of industry experience to UChicagoTech. As Head of Venture Investments, Abbott Biotech Ventures, Inc., Steve was responsible for leading the evaluation and execution of equity investments in emerging pharma and biotech companies of strategic interest to Abbott. Prior to joining ABVI, Steve served in a range of roles, including director of Abbott's Global Pharma Licensing Group, director of the Technology Licensing Group, and director of the Abbott Decision Support Group. Steve received his B.S. in Biochemistry from Michigan State University and his Ph.D. in Biochemistry and Molecular Biology from Northwestern University.

Albert A. Lauritano, MS, CLP
Technology Licensing & Collaboration, BD Technologies)

Albert Lauritano is Director, Technology Licensing & Collaboration for BD Technologies.  He joined BD in 2003 and directs a team of business development professionals responsible for technology sourcing, evaluation, development and commercialization.  He is also responsible for the center's technology transactions, innovation activities and life science incubator – established in 1999 to foster partnership with innovative companies emerging from local and regional academic centers.  He is a member of Licensing Executive Society, Association of University Technology Managers and American Diabetes Association. Albert has over 35 years of experience in the pharmaceutical, biotechnology and medical technology industries.  Prior to joining BD Technologies, he held executive business development positions at Amylin Pharmaceuticals, Icagen Inc. and D-Pharm Ltd. where he established collaborations with pharmaceutical and biotech companies and was responsible for global in and out licensing activities with companies and universities. Earlier in his career, he worked at Novo Nordisk Pharmaceuticals where he served in senior clinical research, marketing and business development positions in the US, Canada, Europe and Japan.  He has numerous publications in the field of diabetes and received the professional designation Certified Licensing Professional™ in 2008.

Burton Lee, Ph.D., MS, CLP
Lecturer, European Entrepreneurship & Innovation, Stanford University, School of Engineering and Managing Director, Innovarium Ventures)

Based in Silicon Valley, Dr. Burton Lee lectures on European Entrepreneurship and Innovation in the Stanford School of Engineering, where he is considered one of Silicon Valley’s leading experts on the European innovation ecosystem, startup and venture finance, corporate and university innovation, and government innovation policy scenes. While at Stanford, over the past five years he has successfully developed and executed partnerships with European national and regional governments, venture finance organizations and industry in Sweden, the United Kingdom, Denmark, Italy, Finland, Norway, Ireland, France, Spain, Romania and Estonia. Dr. Lee concurrently serves as Managing Director of Innovarium Ventures, a financial, technical and strategic advisory services firm with technology startup, angel investor, venture capital fund, university, corporate and national and regional government clients in Europe, Latin America and the USA. Current/recent engagements include Sophia Tech Park (Bulgaria), the Gdansk Metropolitan Authority (Poland), the German Silicon Valley Accelerator, Ireland’s University of Galway (NUI Galway), Denmark’s Midt Jutland Region and Aalborg University, the Universidad de los Andes Engineering School (Bogota), as well as the TIVIT ICT Industry Association (Finland), the CETICS ICT Industry Association (Colombia), and the CAPATEC Chamber of Commerce of Technology Companies (Panama). Burton’s professional history encompasses 15+ years entrepreneurial, investment and senior executive leadership and advisory experience in venture-‐backed technology startup companies; venture capital and private equity funds; angel investor networks; global technology corporations (Daimler, HP and General Electric); federal S&T agencies (NSF, NIH and NASA); the European Commission (serving as an FP7 expert evaluator); research universities, and national and regional governments. He is a researcher and frequent conference speaker and media commentator on the US and European entrepreneurship, innovation ecosystems, university reform, regional economic development, venture finance, university commercialization, social media and product design scenes. During 2009-‐2010, he served as the sole non-‐Irish member of Ireland’s national Innovation Taskforce, appointed by Prime Minister Brian Cowen. He is a recognized global expert on innovation ecosystems and policy, technology startup companies, venture finance, university-‐ based innovation models, the role of product design and design thinking in building innovation regions, and new approaches to technology cluster development. Dr. Lee holds a PhD in Mechanical and Electrical Engineering from Stanford, and an MBA in Finance and Entrepreneurship from Cornell University.

Ben Littauer
(Angel Investor,
Boston Harbor Angels and Walnut Venture Associates)

Ben Littauer is an angel investor with expertise in Internet and communications technologies, as well as healthcare IT. Currently an active member of Boston Harbor Angels and Walnut Venture Associates with investments in a wide variety of startups, he sits on the boards of two portfolio companies. He is a mentor for Mass Challenge and The Capital Network, and is on the advisory board at TCN. Mr. Littauer is a judge for Mass Challenge, MITX Innovation Awards, and various academic competitions. Mr. Littauer was Technology Strategist for Beth Israel Deaconess Medical Center in Boston, where he defined the architecture for PatientSite, allowing patients to communicate securely with their healthcare team and view their own medical records. He was a consultant to the Massachusetts Health Data Consortium on healthcare data security projects. Mr. Littauer was co-founder, President, and CTO of Baranof Software, the leading vendor of service-level management software for messaging and Internet applications. Baranof was sold to Tally Systems in 1997. He has worked for Cisco Systems, Sun Microsystems, Symantec, Lotus, and BBN. Mr. Littauer was also an analyst with Ferris Research and Baroudi Bloor International.

Robert Locke
(Vice President, Open Innovation,

Robert is Vice President, Open Innovation at Tyco (TYC). He joined Tyco in October of 2008 with the acquisition of Vue Technology, where he was CEO. Robert has over 25 years of experience in operations, finance and M&A. He has held a number of executive and entrepreneurial positions including Venture Partner at J.P. Morgan Capital and founder of Kelmscott Communications, a $100 million graphic arts company that was sold to Consolidated Graphics (CGX) in 2005. Early in his career Robert spent 6 years in sales with IBM. He graduated with distinction from U.C. Berkeley with a B.A. in Economics. Lowell
(Director, Advanced Business Development, Faurecia xWorks)

Dana Lowell is a graduate of Western Michigan University, where he received a B.B.S. degree in Business Management. He subsequently earned a MBA from Oakland University in 1986. Dana has served as Market Strategist at General Motors, Sales & Marketing Director of Stanley Tools, Marketing Director for Prince Automotive, as well as Director of Business Development for Johnson Controls before joining Faurecia in 2006. As Director of Advanced Business Development at Faurecia’s award winning xWorks Innovation Centers, Lowell is responsible for bringing new ideas to market and for identifying key partnership opportunities through open innovation models across a global network with facilities in Holland MI, Silicon Valley, Shanghai, and Munich. Faurecia xWorks is a cross functional product & business incubator focusing on strategic innovation. xWorks employs a “lean” pre-development activity heavily focused on leveraging technology partnerships and existing development initiatives. Primary focus is to develop an advantaged portfolio of consumer driven product solutions for the automotive market sector. Maas
(Project Manager, University of Akron Research Foundation and Assistant Vice President, University Innovation Ventures)

Andrew Maas is a Project Manager for the UA Research Foundation and Assistant Vice President of University Innovation Ventures. Mr. Maas prepared, submitted and won the inaugural Economic Development Administrations’ 2010 i6 Challenge Grant, which awarded $2.2M to the Austen BioInnovation Institute in Akron and the UA Research Foundation. Mr. Maas also assists with intellectual property and related emerging enterprise matters; evaluating technologies, markets and preparing related summaries; and developing strategies and promotional materials. Mr. Maas is a Licensed Professional Engineer in the state of Texas and a licensed attorney in the state of Ohio. Mr. Maas has published articles on cementitious materials, intellectual property, and technology commercialization. Mr. Maas has degrees from Brigham Young University (B.S.) The University of Texas at Austin (M.S.E.) and the UA (J.D., LL.M. – Intellectual Property). He is active in the American Intellectual Property Law Association and the Cleveland Intellectual Property Law Association. Magid
(Director, Software Strategy, IBM Venture Capital Group)

Deborah Magid represents IBM’s $25 B software business in the company’s 12-year old Venture Capital Group. Her expertise spans several industries. Deborah is responsible for sharing insights about emerging markets, technologies, and business models with venture firms and entrepreneurs around the world. She scouts for emerging business opportunities, and shares views on innovation and growth areas of the market. As a director of strategy in IBM Software Group, she also brings insight from the venture community to the development of IBM’s growth strategies. Deborah is responsible for fueling the ecosystem pipeline in strategic areas related to building a “smarter planet” and contributes to filling out the IBM product portfolio through M&A. Deborah’s relationships are global and extend into emerging geographies. Deborah is a frequent spokes-person on topics of relevance to entrepreneurs and investors. She is Chairman of the Board of SVForum, the Silicon Valley emerging technology network; on the advisory board of White Bull, serving the European entrepreneurial and venture communities; and on the Steering Committee of the California Sustainability Alliance. Previously, Deborah held positions in product management, marketing, and user-centered design at Taligent, GE Information Services and AT&T. Deborah holds degrees in Cognitive Psychology from the University of Pennsylvania and the University of Connecticut. Maiocco
(Director, Microsoft Ventures Fund)

James is Director for Microsoft Ventures Fund, focused on early-stage, seed investments. Prior to Microsoft, James was an entrepreneur and executive for several years in high-growth online startups. Earlier in his career, James was a business attorney focused on venture capital financing and intellectual property. Mawson
(Founder and Editor-in-Chief, Global Corporate Venturing and Global University Venturing)

James was editor of Private Equity News, part of Dow Jones and The Wall Street Journal in London, for nearly four years until May, 2010 when he launched Global Corporate Venturing as an independent title from his own publishing company. This was followed by the launch of the second publication, Global University Venturing, in January 2012 to help students and faculty and academia more broadly launch or develop their entrepreneurial businesses and work with external peers. As well as editing Private Equity News, James coordinated leveraged buyout and venture capital coverage for use by other titles in the Dow Jones and News Corporation group, acted as a spokesman on BBC radio and television and chaired awards and conferences for a host of media groups, including the BVCA awards and event for more than 1,000 people in October, 2009. Previously, James had freelanced for a host of national and trade media titles, including the BBC, Financial Times, Economist, Independent on Sunday, Sunday Express and Dow Jones Newswires; provided research for Nick Davies's book, Flat Earth News; was a foreign correspondent in central and eastern Europe; and was international editor for FT Business. After graduating from King's College, London, James's first job was working at technology publishing house ComputerWire. He has also been a director of the London Press Club and has acted as a pro bono editor for the European Venture Philanthropy Association's monthly newsletter. P. McCarter, M.D., Ph.D
(Entrepreneur in Residence (EIR), Monsanto Growth Venture)

James P. McCarter, M.D., Ph.D. is Entrepreneur in Residence (EIR) with Monsanto Growth Ventures, Senior EIR with BioGenerator, and Adjunct Professor of Genetics, Washington University School of Medicine in St. Louis. He works with Monsanto colleagues and entrepreneurial networks to identify strategic investments focused on high growth markets and disruptive technologies that create new value propositions. Previously, Jim was the founder, President, and CSO of Divergence, Inc., a world leader in the application of informatics to agriculture and infectious disease. The Company’s discoveries led to three products now in development for agrochemistry, veterinary therapeutics, and diagnostics. In 2011, Divergence was acquired by Monsanto which has advanced its nematicide to phase III in its pipeline. Jim is a co-author of over 50 scientific papers. He is the recipient of the Innovation Award from the Academy of Science of St. Louis and a Crown Fellow of the Aspen Institute. McCoy
(Executive Director - Corporate Engagement Office, University of Oklahoma)

Cameron is the Executive Director for the Corporate Engagement Office at the University of Oklahoma. Prior to joining OU, he worked for Simon Property Group and TXU Energy in Dallas, TX and served eight years in the US Army. McCoy holds degrees from Washington State University in Architectural Studies, History, and Social Studies and a Masters degree from the University of Oklahoma. Cameron is currently finishing his dissertation studying University-Industry interactions. He serves on several non-profit and industry Boards of Directors.

Matt McElhattan
(Venture Principal, Chevron Venture Capital)

Matt McElhattan has more than 15 years of industrial experience serving in both technical and consultative capacities at small private companies and large public companies. Prior to joining Chevron, McElhattan worked at several venture backed startups doing business development and project management. As a management consultant for PricewaterhouseCoopers’ supply chain practice he was focused on deploying Web-based supply-chain models and completing integrated supply-chain analysis for a variety of clients in the high tech sector. Earlier McElhattan led market and feasibility analysis for new technologies at Ducker Worldwide, focusing on market size, product design, segmentation and target applications. Matt is currently the Board Observer for Modumetal, RealityMobile and Sample6.

Brad McManus
(Co-Founder and General Partner, Capbridge Group)

Brad is co-founder and General Partner of Capbridge Group, a Silicon Valley based corporate venture fund management firm. Capbridge custom-builds and manages strategic venture funds for corporations seeking new business growth in targeted vertical market areas. Each Capbridge fund has a focused investment theme established in consultation with the corporate LPs. Partnering among the corporate LPs and with the venture startups, which provide the seeds of innovation, offers a unique go-to-market platform for successful business strategies and exceptional financial returns. Previously, Brad served as head of the Panasonic Venture Group, the strategic venture capital unit of the global leader in consumer electronics. Based on an Open Innovation imperative, PVG’s dual mission is to (1) to create innovation based collaborations with venture backed companies and (2) strengthen relationships through ROI based venture investments. He directed the strategies to identify the growth opportunities for Panasonic, source and evaluate venture backed company targets and structure mutually rewarding alliances. He was also senior advisor on the $30M investment in Tesla Motors. Portfolio includes Kovio, Entropic, Techwell, P-Cube, Ikanos, Gracenote, Pixel Optics, Ooyala and SBA Materials and many stealth deals.

Luis R. Mejia
(Senior Associate, Office of Technology Licensing, Stanford University)

Mr. Mejia is a Senior Associate in the Office of Technology Licensing at Stanford University. He manages a portfolio of over 300 technologies ranging from biotech to cleantech, including Stanford’s two biggest patented cases. In his 25 years at Stanford, he has managed three major patent litigations (including two cases argued before the US Supreme Court), negotiated over 250 licenses, and evaluated over 700 inventions, including the PageRank Algorithm which was the instrumental IP that led to the creation of Google. Mr. Mejia has been an advisor to Silicon Valley start-ups, Los Alamos National Laboratory, Monterey Bay Aquarium Research Institute and is a Board Member of the Stanford University OTL, LLC. Mr. Mejia received his engineering degree in Mechanical Engineering from Arizona State University and is a Certified Licensing Professional. Prior to joining Stanford he worked on solar energy systems and energy management at Honeywell and Pacific Gas & Electric. Mr. Mejia is a Fellow of the Disruptor Foundation.

images/conference2013/speaker/mukherjee.jpgPulakesh Mukherjee
(Principal, BASF Venture Capital)

Pulakesh Mukherjee joined BASF Venture Capital as Principal in 2009 and is based in Silicon Valley, California, USA. He began his career in 2002 in Polymer Research at BASF in Germany where he was responsible for development and scaling up of novel water based polymers. After his stint in research he joined the Intermediates Division and was delegated to India where he was Head of New Business Development of the Intermediates Division as well as responsible for marketing and sales of specialty chemicals for the Pharmaceutical Industry. Pulakesh has international expertise in research & development, marketing, sales and business development. He received his PhD from Stanford University, USA and has published in peer-reviewed journals and has co-authored more than 20 patents. Pulakesh represents BASF in the Board of Allylix, Solidia Technologies and Arcadia BioSciences as either director or observer. He also serves as advisory at NREL VC Advisory Board and Stanford Energy Club.

images/conference2013/speaker/mukhopadhyay.jpgBibhash Mukhopadhyay, Ph.D.
(Manager - Business Development Group, Global Surgery Division, Johnson & Johnson)

Bibhash is a Manager in the Business Development Group at Johnson & Johnson’s Global Surgery Division. His responsibilities include identifying and building strategies around new growth space opportunities and leading cross functional teams for deal sourcing, evaluation & transactions for investment, licensing & acquisition activities. Previously, he worked as a part of Oncology Business Development group in the Pharmaceutical division and Corporate Office of Science & Technology, the Corporate R&D partnering arm of Johnson & Johnson, on commercial evaluation of assets for R&D partnering, licensing or acquisition, scientific diligence on venture transactions and led an investment in a start‐up using a novel hybrid model of financing. He also initiated and led an internal effort on repurposing compounds de‐prioritized from the late development portfolio, participated in strategy development in Lung Cancer and Ophthalmology, built the scientific case for an internal venture developing an innovative treatment of neurodegeneration and optimized portfolio reporting metrics for departmental management team. Prior to joining J&J, Bibhash gained experience in venture investing as an Intern/Associate at Burrill & Co, as a part of the Pharmaceutical Equity Research team at Rodman & Renshaw, as a Business Development Consultant with Bellicum Pharmaceuticals, as a Consultant to Essex Woodlands Health Ventures and Sante Ventures, as an Associate in Rice University’s Office of Technology Licensing and as an Advocacy Program Leader at United Nations Development Program. Bibhash graduated from Baylor College of Medicine/Rice University, Houston with a PhD in Biomedical Sciences completing a dissertation on pathophysiology of retinal degeneration, where he acquired technical expertise in Oncology, Neuroscience, Immunology and Ophthalmology. He also has a Masters in Neuroscience/Computational biology from the Max Planck Research School, Germany and an undergraduate degree from All India Institute of Medical Sciences, during which he completed research internship at Weizmann Institute of Science in Israel.

images/conference2013/speaker/01pace.jpgJulie Nagel, Ph.D.
(Executive Director, Corporate Partnerships, University of Kansas)

Julie S. Nagel is the Executive Director of Corporate Partnerships at the University of Kansas and the University of Kansas Medical Center. In this role, she is developing a university wide strategy to consolidate industrial relations and is implementing large scale programs to involve industry in translational research in areas of excellence at KU. Prior to KU, she was the Managing Director of the Oncological Sciences Center in Discovery Park at Purdue University. Julie received a Ph.D. from the University of Tennessee, Knoxville in Environmental Toxicology where she was the recipient of an International Philanthropy Education Organization (PEO) Scholar Award, University of Tennessee Science Alliance Award for Outstanding Scholarly Achievement by a Graduate Student, and an Arthur E. Yates Graduate Fellowship. She did postdoctoral training at the Institute of Toxicology at Wayne State University. She left the University as the 13th employee of a start-up company from the University of Michigan. As Technical Coordinator, for Rubicon Genomics, Inc., she was responsible for developing a federal funding pipeline into the company. Dr. Nagel then joined Biotechnology Business Consultants, LLC in Ann Arbor, Michigan as Program Director where she successfully directed both statewide and regional programs providing assistance to Life Science entrepreneurs. She has developed and implemented numerous programs to assist early stage life science entrepreneurs including a federal grant opportunity matching program and a federal grant strategy program. At Purdue University, Julie managed the portfolio of interdisciplinary cancer projects including the Cancer Care Engineering project, an $8M multi-institutional project where she established and managed three clinical sites including a community hospital/practice based site. She has been instrumental in establishing partnerships and creating large projects and programs to translate technology in the academic setting.

images/conference2013/speaker/peterson.jpgMaria Peterson, Ph.D.
(Program Director, Emerging Technologies, JSR Micro, Inc)

Maria Peterson is Emerging Technologies Program Director for JSR Micro, Inc in Sunnyvale, CA. JSR is a specialty materials company with headquarters in Tokyo, Japan. JSR’s core products are materials for use in semiconductor and display manufacturing, and for automotive applications. With the JSR Emerging Technologies team, she is engaged in identifying and growing new business opportunities in areas of energy storage, green chemistry, OLED, and others. Maria has been with JSR since 2004. Prior to JSR, she was Technical Marketing Director for Cabot Microelectronics, a global leader in semiconductor polishing slurries, and she was Applications Engineering Manager for EKC Technology (now part of DuPont), developing and promoting polishing and cleaning materials for semiconductor applications. Maria earned her PhD from Stanford University in surface geochemistry. Her MS is from UC Berkeley, and BA from Carleton College.

Padmaja Ruparel
(President, Indian Angel Network (IAN))

Padmaja Ruparel is an Angel Investor and President of Indian Angel Network (IAN), India's first and now one of Asia's largest group of business angels, comprising the who's who of successful entrepreneurs and dynamic CEOs from India and overseas. With a wide range of experience of over 25 years, Padmaja has been a key player in the entrepreneurial eco system of India. She has been key in reviving the Indian Venture Capital Association, India's oldest and largest association of VC and PE firms as CFO of the organisation. Padmaja is a key member of the Infinity Innovation Fund team, a Rs. 250 crores early stage venture capital fund. Padmaja is deeply involved in India’s path breaking Impact investing initiative – the “India Inclusive Innovation Fund”, a US$1 bn dollar fund which focuses on the Base of the Economic Pyramid. This unique initiative has been seed funded by the Government of India, bringing in public, private and development fund investors, architected to be driven by professional management and promises both financial and impact returns. This is an initiative undertaken by the Prime Minister’s National Innovation Council.

Aleda Schaffer
(Strategic Partnerships Manager, American Airlines)

Aleda Schaffer is a creative business strategist who works with startups around the Bay Area to grow their businesses through American Airline’s Innovators Initiative. Aleda finds and vets select startups to support with travel grants, marketing resources and connections with American’s employees, departments and customers. In addition, she is building long term relationships with high growth entrepreneurs, venture capitalists, angels, incubators and accelerators. Aleda has an MBA from Johnson at Cornell University and a BS from Northeastern University. She currently lives in the bay area with her adoring husband and son.

Shalin Sheth
(Senior Associate, Second Century Ventures)

Shalin is a Senior Associate with Second Century Ventures, the venture capital arm of the National Association of REALTORS® where he identifies, evaluates and executes investments and support existing portfolio companies. Shalin has also played a critical role in the launch and operations of REachTM, SCV’s innovative strategic technology accelerator program launched in 2012. Prior to Second Century Ventures, Shalin worked at Google where he developed sales strategy for its daily deal product. Shalin also worked for Tabula, a venture backed Silicon Valley start-up, where as Product Manager he set the direction of its cloud based software tools resulting in the alpha release to the first set of customers. Shalin was on the Board of Directors and remains active with the Foundation for Freedom, an education based non-profit promoting literacy. He is a startup advocate and regularly advises startups. Shalin holds an MBA from Kellogg School of Management and has earned a MS and BS in Electrical and Computer Engineering from Carnegie Mellon University.

Jennifer Shieh, Ph.D.
(Program Director, SBIR Development Center, National Cancer Institute, NIH)

Dr. Jennifer Shieh is a Program Director at the National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center, focused on strategic initiatives including evaluation, communications and outreach activities, the Investor Forum, and the workshop on Federal Resources to Accelerate Commercialization. Jennifer joined the center as an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow, leading implementation of new SBIR/STTR legislation. Before joining, she was a biology associate at Syapse, a Palo Alto-based startup that creates cloud-based software applications to enable personalized medicine. She also assisted with design and business strategy at Subversus Interactive, a mobile games startup. As a Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences, she developed public programs and aided the design of the new Life Lab exhibit at the Koshland Science Museum. Jennifer studied brain and cognitive sciences at MIT, then earned her PhD in neurosciences at Stanford University. She is the co-author of the textbook Guide to Research Techniques in Neuroscience.

Ben Shih
(Partner, Jafco Ventures)

Ben Shih is a Partner at Jafco Ventures, which he joined in 2003. Ben began his venture capital career with Crystal Ventures, where he focused on a wide variety of early-stage technology investments. Prior to that, he was an analyst for MDT Advisers (Federated Investors), a multi-billion dollar asset management firm. At MDT, Ben was a key member of the team that developed and managed a quantitative hedge fund strategy that deployed $400 million of capital in the U.S. public equities market. Earlier in his career, he spent time as a software developer at Lotus Development (IBM). Ben earned an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar. He received Master of Engineering and Bachelor of Science degrees in electrical engineering and computer science, along with a Bachelor of Science degree in management science, at the Massachusetts Institute of Technology.

Lilia Shirman
(Managing Director, Golden Seeds)

Lilia Shirman is a technology industry executive, author, advisor, and angel investor. She is a Managing Director at Golden Seeds, a nation-wide investor network that maximizes returns by investing in companies whose management teams include women. Lilia is also the CEO of The Shirman Group, a strategy consulting firm that helps technology innovators develop and execute go-to-market strategies that maximize customer relevance. Shirman Group clients include leaders like VMware, EMC, CA, Convergys, and Symantec, and rapidly growing new ventures. Lilia is the author of 42 Rules for Growing Enterprise Revenueand a Mentor in Stanford University’s Global Entrepreneurial Marketing Program. Previously, Lilia held leadership roles at Applied Materials, Accenture, BEA Systems (now Oracle) in operations, strategic planning, marketing, business development, and alliance management. She earned her BS in Engineering from UC Berkeley, and MS in Technology Management from Stanford University.

Stephen J. Socolof

(Managing Partner, New Venture Partners LLC)

Stephen Socolof is a Managing Partner of New Venture Partners LLC (“NVP”).  With over $700 million under management and offices in the US and Europe, NVP is the leading global venture capital firm specializing in corporate spinout venturing.  NVP works closely with corporations to commercialize and scale up new innovations as standalone ventures.  NVP itself was spun out of Lucent Technologies, where it had been an incubator for spinout opportunities from Bell Labs.   NVP focuses on communications and information technologies as well as energy and materials.  In addition to Steve’s firm management responsibilities, he leads deals in semiconductors, software, storage, and wireless technologies.  He is currently a director of Alverix, CrossFiber, EverSpin Technologies, GainSpan Corporation, Own Products, and a board observer of Intelleflex.  He was recently a director of Sychip, Inc. (sold to Murata) and an observer of Flarion Technologies, Inc. (sold to Qualcomm), and Silicon Hive (sold to Intel).

James C. Spohrer, Ph.D.

(Director, IBM University Programs, IBM)

Dr. James (“Jim”) C. Spohrer is IBM Innovation Champion and Director of IBM University Programs (IBM UP). Jim works to align IBM and universities globally for innovation amplification. Previously, Jim helped to found IBM’s first Service Research group, the global Service Science community, and was founding CTO of IBM’s Venture Capital Relations Group in Silicon Valley. During the 1990’s while at Apple Computer, he was awarded Apple’s Distinguished Engineer Scientist and Technology title for his work on next generation learning platforms. Jim has a PhD in Computer Science/Artificial Intelligence from Yale, and BS in Physics from MIT. His current research priorities include applying service science to study nested, networked holistic service systems, such as cities and universities. He has more than ninety publications and been awarded nine patents.

Param Sreekanth
(Director, DuPont Ventures)

Param works at DuPont Ventures, the corporate venture arm of DuPont. He focuses on investment opportunities in industrial biosciences, agriculture, and food & nutrition. He has worked across DuPont in end-to-end business development and M&A transactions, strategy development, financial analysis & valuations, and business plan screening. Prior to DuPont, he spent 5 years in the automotive and engineering software industries. Param has an M.B.A. from the Wharton School of the University of Pennsylvania, and has bachelors and master’s degrees in Mechanical Engineering.

Tony Stanco
(Executive Director, National Council of Entrepreneurial Tech Transfer –

Tony Stanco, Esq. is the executive director of the Angel Investors of Greater Washington, executive director of the National Council of Entrepreneurial Tech Transfer. Previously he was the director of the Council of Entrepreneurial Tech Transfer and Commercialization (CET2C) of The George Washington University. Mr. Stanco was a senior attorney at the Securities and Exchange Commission, where he worked on more than two hundred IPOs. He also has worked on innovation policy, including start-up creation and funding by angel investors and VCs. At School of Engineering and Applied Science at The George Washington University, Mr. Stanco works with universities and governments around the world on innovation policy, start-up finance policy, software policy, Open Source, cyber-security, and e-Government issues. Mr. Stanco has appeared before the US Congress, various US defense and civilian agencies, the World Bank, the European Commission, United Nations, Inter-American Development Bank, Organization of American States, World Summit on Information Society, LinuxWorld, Advanced Computer and Internet Law Institute, and International Computer Law Association. Mr. Stanco teaches the Lab to IPO course dealing with start-up formation and funding. He has an LL.M. from Georgetown University Law Center in securities regulation and is licensed as a lawyer in New York state.

Cory Steffek, Ph.D.
(General Manager, Aramco Energy Ventures - Houston Office)

Cory Steffek is the General Manager of the Houston office at Aramco Energy Ventures (AEV), the corporate venturing subsidiary of Saudi Aramco.  He is responsible for identifying technology investments of strategic importance in the areas of: upstream oil & gas; downstream oil & gas and value-added products; renewable energy; energy efficiency and water. Before joining SAEV, Cory was in Corporate Development and Strategy at First Solar, where he was responsible for strategic investments and acquisitions with emphasis on new technologies and products.  Prior to First Solar, Cory was at the Altira Group, an energy-focused venture capital firm, where he led investments in a broad range of energy technology companies.  In addition, he has also held several management roles in product development and engineering at PPG Industries.  He holds a PhD in materials chemistry from the University of Michigan and an MBA from The Kellogg School of Management at Northwestern University.

Dušan Stojanović
(Founder and Director, True Global Ventures)

A "citizen of the world" born in Sweden and still with a Swedish passport. Has worked for more than 20 years within Business Development primarily in E-payments/E-Commerce and financial services. Half of the time at GE Capital and and the rest with his own ventures/investments. Possessing a strong international network in Stockholm, Paris, Berlin, New York, the SF Bay Area, Beijing, Shanghai and Hong Kong. He speaks 6 languages and as many cultures and working habits. Dusan was voted European Angel of the Year 2013 by the European Business Angel Network (EBAN).

Deborah R. Stokes
(Director, External Research, Huawei Technologies, USA)

Deborah R. Stokes is the Director, External Research, at Huawei Technologies, USA, responsible for collaborating with universities and research institutions across North America. Deborah has served in various technology leadership positions for over 25 years. She started with what was known as BNR (Bell Northern Research) in Research Triangle Park in 1987. Prior to that, Deborah managed the National Science Foundation Industry/University Collaborative Research Center in Communications and Signal Processing at North Carolina State University. Deborah served in a number of roles in Nortel including the Wireless Networks business division where she managed various business development, executive support, and communications programs. She returned to the R&D team in 2000 as part of the Advanced Technology Investment team, where in addition to External Research program responsibilities, she was an active member of the Wireless Mesh Network project team, managing the contributions of the MIT Media Lab to this joint product development. Deborah’s responsibilities as part of the Office of the CTO for Nortel included External Research, delivery of the Nortel Technical Conference, and Corporate Compliance. Additionally, she held the role of General Operations and External Research Director for Nortel's Enterprise Solutions business. Deborah has an additional 10 years experience in education, including a role as a Director in the Continuing Education Program at Coastal Carolina Community College. Deborah has served on numerous local business committees and various university advisory boards. She currently serves as the Chair of the IAB for the NCSU FREEDM energy research center and is a member of the University of Texas Dallas Telecommunications Advisory Board, MIT Media Lab Program Committee, University of New Mexico ECE IAB and NCSU Computer Science IAB. She also participates on the PARC Innovation Council and the SVIE group. Deborah has given many presentations on best practices in external research and innovation. She has numerous publications in the technology management field, and has filed a patent on measuring the ROI from university investments. Deborah has a BS in Business Administration, and completed her Executive MBA at the University of Texas at Dallas in 1994, with a focus on "Managing for Change".

Sebastian Titz, Ph.D.
(Investment Manager, 3M New Ventures)

Sebastian Titz is an investment manager of 3M New Ventures, the corporate venture arm of 3M in North America. He identifies and invests in disruptive new technologies and start-up companies of strategic relevance for 3M. His investment interests include health care, sustainability, advanced materials and electronics. Before joining 3M he did research in Science and Technology Management focusing on post-acquisition collaboration at the University of Naples and worked as a consultant within FIAT. Sebastian has a M.S. in Industrial Engineering and Management. He also holds a PhD in Engineering and a Master in Business Administration.

Rafael Torres
(Senior Managing Director, Healthcare, GE Ventures)

Rafael Torres is the Senior Managing Director and GE Ventures, Healthcare leader, where he leads the VC team for Healthcare investments. Previously, he led GE Equity Healthcare investments and acquisitions and integrations at GE Healthcare, where he had been a key driving force behind the healthcare investing since its inception. Rafael has spent 11 years investing in healthcare in GE across the healthcare space, and prior to joining GE in 2001, held various positions at The Boston Consulting Group, AT Investments (a Latin American venture capital fund) and Citibank.

Glenn Vonk, Ph.D.
(Director, Advance Technologies, BD Technologies)

Glenn Vonk is Director of Advance Technologies at BD Technologies, NC, where he is responsible to source new technologies for critical health needs aligned with BD strategies.  Previously, Dr. Vonk led and established life sciences R&D at the Singapore BioVenture Centre with programs in media development, infectious disease diagnostics, and bioinformatics.  Dr. Vonk also led technology development in drug delivery, immune and nucleic acid diagnostics, and e-health and is a co-inventor on over 25 issued patents.  These activities have significantly contributed to BD’s Diagnostics, Diabetes, and Asia-Pacific businesses. Dr. Vonk previouslt had business development roles with the Singapore EDB, multiple science institutes and academic institutions including MIT and the National University of Singapore. He remains engaged with new technology development and enjoys working across disciplines and functions in a global organization.

Mark Vreeke, Ph.D.
(Co-Founder, Chemical Angel Network)

Dr. Mark Vreeke is a cofounder of the Chemical Angel Network.  The Chemical Angel Network brings together entrepreneurs and investors who are working on deals with a strong Chemistry component.  Mark’s specialties are in the broad areas of medical devices/diagnostics, information technology, and energy transportation. Mark is also one of the founding partners at Rational Systems. Rational Systems’ enterprise software is installed on four major interstate gas pipelines and multiple smaller gas transportation and storage assets. It is currently responsible for managing the transportation of 15-20% of the entire US natural gas market. Prior to and during his tenure at Rational Systems, Mark was employed by several medical device and diagnostic firms including Pepex Biomedical, SpectRx, TheraSense, Bayer and Hospira. His roles ranged from Research Scientist to Senior VP of R&D. Of particular relevance was TheraSense. Mark assisted with the transfer the Wired Enzymetm technology from the University of Texas to TheraSense. This technology formed the basis for a successful product launch and the eventual purchase of the company by Abbott for $1.2 billion in cash. Mark earned a BS in Chemistry from Calvin College and a PhD in Chemistry from the University of Texas at Austin. Academic honors include a Welch Fellow, a Woodrow Wilson Fellow and the accreditation of Professor by the ACQ in Spain.

David Wells
(Partner, Greentech Practice, Kleiner Perkins Caufield & Byers)

David Wells joined Kleiner Perkins Caufield & Byers in 2006 and is an operating partner in the firm’s greentech practice. David builds relationships with scientists, entrepreneurs and technologists, creating knowledge maps and sourcing investment opportunities across the entire greentech landscape with a focus on disruptive order-of-magnitude and tipping-point innovations in the physical sciences. He has helped bring many ventures through the KPCB investment process, including due diligence, investment structuring, team building and goal setting for companies including Aquion Energy, FloDesign Wind Turbine, Modular Wind Energy, Primus Power, Siluria Technologies, Solidia Technologies and several ventures still in stealth stage. David’s background includes 10 years of technical experience in shipboard and marine engineering, and eight years building and selling a nationwide business in Japan. David helped create and build the KPCB Greentech Innovation Network, a group of business, academic and policy leaders formed to identify and pursue critical greentech innovations. He serves on the Board of Advisors of the National Renewable Energy Laboratory, and on the Advisory Committee of the Energy Research, Development and Deployment Policy Project at the Harvard University John F. Kennedy School of Government. David frequently speaks at academic and commercial greentech conferences about innovation and investing.

Allen Yeung

(Chairman, Hong Kong Business Angel Network)

Mr. Allen TB Yeung, Chairman of Hong Kong Business Angel Network, he also holds the position of Vice President, Business Development and Technology Support at Hong Kong Science and Technology Parks Corporation. Ir. Yeung is responsible for incubating technology and innovative design startup companies, creating synergies among industry and academic sectors, and providing advanced laboratory support facilities for innovation and technology development. In this capacity, he works with government organisations, non-profit organisations, industry, associations, and investment community groups to promote technology development in Hong Kong. He is the Advisor to the EE Department of The Chinese University of Hong Kong and Advisory Committee Member of The Hong Kong Polytechnic University. Mr. Yeung has served as judge at various awards and business plan competitions, including the Hong Kong Award for Industries; ICT Awards, Massachusetts Institute of Technology - CHIEF (China Innovation and Entrepreneurship Forum); HK University of Science & Technology Entrepreneurship Competition; Young Entrepreneurs Development Council’s E-Challenge; Vice Chancellor’s Cup of the Chinese University of HK; PCM BIZ.IT Excellence by Sing Tao Magazine Group Limited; HKEIA Award for Outstanding Innovation & Technology Products; and Hong Kong Polytechnic University Micro Fund.



Please publish modules in offcanvas position.